Asia-Pacific Insulin Market

The insulin market in APAC is expected to grow from US$ 7,288.17 million in 2022 to US$ 14,936.00 million by 2028. It is estimated to grow at a CAGR of 12.7% from 2022 to 2028.

Regeneration of Artificial Pancreas with Advanced Transplants to Emerge as Significant Therapeutic Trend

Body cells naturally produce small molecules, hormones, and proteins to keep the body functioning properly. The artificial pancreas can control blood sugar levels for people with type 1 diabetes better than the standard treatment. In people with type 1 diabetes, continuous glucose monitoring (CGM) devices provide around-the-clock information on blood glucose levels, which is used to determine the need/dosage of insulin. Insulin pumps allow the subcutaneous administration of insulin doses throughout the day. Despite frequent monitoring of blood sugar levels and dose adjustments, insulin injections do not ideally recreate the natural waves of insulin released from the pancreas. This leaves patients continually working to avoid chronically high or low blood sugar, which can cause blindness, diabetic coma, or life-threatening insulin shock. Various research groups have been working on technologies for regenerating pancreatic cells. These technologies are expected to prove promising for addressing the conditions associated with diabetes in the coming years.

Market Overview

Asia Pacific (APAC) is the fastest-growing market for insulins. The market in APAC is subsegmented into China, India, Japan, South Korea, Australia, and the Rest of APAC. The growing prevalence of diabetes and rising incidence rates of lifestyle-related disorders such as obesity drive the market growth in the region. Several market players are focusing on countries in Asia Pacific for geographic expansion and other strategies. Therefore, the region holds a huge potential for insulin market players. The demand for insulin in China has increased in the past decade. According to PharmExec, China has ~114.4 million diabetic patients. The diabetes market in the country is predicted to reach US$ 6.67 billion in 2022. While other drugs such as DPP-4 inhibitors and GLP-1 agonists are available, insulins remain the country's most commonly used antidiabetic drug. Insulin therapy is the primary treatment for people with type 1 diabetes, as pancreas stops synthesizing the hormone that regulates the body's blood sugar levels. Some people with type 2 diabetes or gestational diabetes need to take insulin when other medications cannot keep blood sugar levels within the desired range. According to Statista, the market volume of human insulin and its analogs in China stood at ~US$ 2.96 billion in 2018, and it is expected to grow at an annual rate of 4.4% through 2030.

APAC Insulin Market Revenue and Forecast to 2028 (US$ Million)

APAC Insulin Market Segmentation

The APAC insulin market is segmented into type and country. Based on type, the market is segmented into long acting insulin, rapid acting insulin, short acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen & needle, and others. The long acting insulin segment registered the largest market share in 2022.

• Based on long acting insulin, the APAC insulin market is sub-segmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment registered the largest market share in 2022.
• Based on short acting insulin and traditional human insulin, the APAC insulin market is sub-segmented into Novolin R, Humalin R, Insuman, others. The insuman segment held the largest market share in 2022.
• Based on concentrated insulin and combination insulin, the APAC insulin market is sub-segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held the largest market share in 2022. 
• Based on biosimilar insulin, the APAC insulin market is sub-segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment held the largest market share in 2022. 
• Based on country, the market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. China dominated the market share in 2022.

Adocia; Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt are the leading companies operating in the insulin market in the region.

Asia-Pacific Insulin Market Strategic Insights

Asia-Pacific Insulin Market Segmentation Analysis

Asia-Pacific Insulin Market Report Highlights

Asia-Pacific Insulin Report Scope

Asia-Pacific Insulin Market Country and Regional Insights